RVPH · NASDAQ
Average $38.15 (+8193.0% upside)
The latest rating actions, newest first
| Firm | Date | Action | Rating |
|---|---|---|---|
| Maxim Group | Apr 8, 2026 | Downgrade | Buy → Hold |
| Roth Capital | Mar 31, 2026 | Maintains | Buy |
| Alliance Global Partners | Mar 30, 2026 | Maintains | Buy |
| D. Boral Capital | Mar 5, 2026 | Downgrade | Buy → Hold |
| Chardan Capital | Jan 5, 2026 | Maintains | Buy |
| D. Boral Capital | Dec 23, 2025 | Maintains | Buy |
| HC Wainwright & Co. | Dec 23, 2025 | Maintains | Buy |
| D. Boral Capital | Nov 19, 2025 | Maintains | Buy |
| D. Boral Capital | Oct 28, 2025 | Maintains | Buy |
| HC Wainwright & Co. | Oct 27, 2025 | Maintains | Buy |
Updated Jun 23, 2026
Reviva Pharma is currently faced with a challenging situation due to a recent reverse stock split, which may impact investor sentiment. However, with a promising pipeline focused on neuropsychiatric and other disease indications, particularly its lead asset brilaroxazine, Reviva has the potential for significant growth and value creation in the long term, reflected in the Buy rating and $2 price target set by Keay Nakae, CFA.
Reviva Pharma is currently a high-risk investment, as the company has a small pipeline with only two drugs in late-stage development, and a weak cash position that will likely require additional fundraising that could result in share dilution. Furthermore, the company's lead drug candidate, Brilaroxazine, has only shown efficacy in one of two phase III trials, indicating potential challenges in obtaining FDA approval. Additionally, there are potential risks to the company's intellectual property and commercial success of its product candidates due to market acceptance and reimbursement challenges. These factors, coupled with the history of poor stock performance following a reverse stock split, lead to a negative outlook for Reviva Pharma's stock.
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.
